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Abstract
Background: Childhood abuse related posttraumatic stress disorder (CA-PTSD) is associated with a high burden of
disease and with treatment response rates that leave room for improvement. One of the treatments for PTSD,
prolonged exposure (PE), is effective but has high drop-out rates and remission rates are relatively low. An
intensified form of PE (iPE) was associated with good response and low drop-out rates in PTSD and has not yet
been tested in a controlled trial in CA-PTSD. Phase-based treatment (PBT), in which PE is preceded by skills training
may improve overall outcomes in this population. We will assess the effectiveness and cost-effectiveness of
standard PE, iPE and PBT in patients with CA-PTSD.
Methods/design: Multi-center randomized controlled trial. Treatment conditions are: prolonged exposure
(PE; maximum of 16 sessions in 16 weeks); intensified PE (iPE; maximum of 12 sessions in four weeks and
two booster sessions); phase-based treatment (PBT; maximum of eight sessions skills training followed by
eight sessions PE in 16 weeks).
Primary outcome: Clinician-rated PTSD symptom severity. Secondary outcomes: loss of PTSD diagnosis, self-reported
PTSD symptom severity, comorbid symptom severity and quality of life. Moreover, we will examine cost-effectiveness
and moderators and mediators of treatment outcome. Target population: adults with CA-PTSD (N = 150). Assessments
in weeks 0, 4, 8, 16, 26 and 52.
Discussion: Given that no consensus yet exists about the treatment guidelines for patients with CA-PTSD, the present
study may have important implications for the treatment of CA-PTSD.
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Background
Childhood abuse is associated with severe negative long-
term consequences. These include health problems, high
health care utilization, a high risk of revictimization, low
socio-economic well-being and criminal behavior in adult-
hood [1–6]. Childhood abuse is also related to many mental
health problems such as depression, suicidality, dissoci-
ation, personality disorders, substance abuse and aggression
[4, 5, 7–10]. In many cases, childhood abuse leads to Post-
traumatic Stress Disorder (PTSD): 22 to 49% of those who
report childhood abuse fulfill criteria for lifetime PTSD
[11]. The treatment of PTSD in this population is relatively
under investigated.
In international guidelines of PTSD, trauma-focused
treatment (TFT) is recommended as first treatment option
[12]. Substantial evidence exists for the effectiveness of
TFT in patients with PTSD [13–15]. Treatment adherence
and efficacy are relatively low, however. A meta-analysis
indicated that 44% of the patients still fulfilled diagnostic
criteria for PTSD at the end of treatment [14]. TFT
may be less effective in CA-PTSD than in PTSD in gen-
eral, because patients with CA-PTSD have more co-
morbid symptoms, such as interpersonal problems and
emotion regulation difficulties [16]. These symptoms
contribute significantly to functional impairment [17]
but are not specifically addressed in TFT. This may
lead to poorer outcomes and specifically less effective
use of trauma focused interventions. The current study
is designed to investigate the effectiveness of two vari-
ants of TFT that may lead to improved effectiveness
and/or adherence compared to standard TFT.
Some authors [15, 18, 19] have argued that trauma fo-
cused treatment (TFT) is the preferred treatment for pa-
tients with CA-PTSD despite earlier mentioned comorbid
symptoms in these patients. A recent meta-analysis indeed
revealed more symptom improvement after TFT than
non-TFT in patients with CA-PTSD [15]. A systematic
review also concluded that there is no reason to exclude
patients with CA-PTSD from TFT [20]. However, the co-
morbid symptoms may make it more difficult for those
patients to attend weekly treatment sessions, and for ther-
apists to keep the focus on trauma treatment. This has led
some researchers to propose that treatment of patients
with CA-PTSD may be improved by intensification of
TFT. Promising results with an intensified form of TFT in
PTSD [21–25] suggest that condensing treatment in a
shorter period of time may lead to faster or better treat-
ment results. Reduction of treatment length may not only
lead to faster improvement, but also to improved treat-
ment adherence, because there is less time between ses-
sions for anticipatory anxiety to build up [24, 26].
Intensive TFT (up to 18 h of cognitive therapy (CT) deliv-
ered in one week) led to faster symptom reduction com-
pared to standard TFT (up to 20 h of weekly CT sessions
delivered in 3months) and equivalent results over 14
weeks [23]. In a veteran population an intensified form of
TFT led to faster symptom decline, while it was as effect-
ive as regular weekly TFT on the long term [22]. With re-
gard to CA-PTSD, results of a controlled case series
design with intensive TFT in adolescents (N = 10) also
suggest that intensive treatment is safe and acceptable,
with an 80% remission rate [24]. Furthermore, results of
two open studies in patients with chronic PTSD following
multiple traumas, including CA, [21, 25] show that inten-
sive TFT was effective and patient retention high (less
than 5% drop-out). Taken together, these studies suggest
that intensive TFT (iTFT) may improve overall effective-
ness of treatment of CA-PTSD.
Other authors [27–30] have argued that the symptoms
and problems frequently observed in patients with
CA-PTSD are characteristics of a distinct form of PTSD,
referred to as ‘complex PTSD’. Complex PTSD is charac-
terized by prominent emotion regulation difficulties,
interpersonal problems and a negative self-concept [30].
The International Society for Traumatic Stress Studies
(ISTSS) guidelines recommend ‘phase-based treatment’
as first treatment option for patients with complex
PTSD [28]. In phase-based treatment (PBT) the first ses-
sions are focused on addressing emotion regulation and
interpersonal problems, which is followed by TFT [31].
This treatment is based on the notion that emotion
regulation and interpersonal problems interfere with
daily life functioning and that reduction or resolution of
these problems can facilitate more effective use of TFT
and can best be addressed before starting TFT [31]. PBT
has indeed been associated with lower drop-out rates
and more complete PTSD remission than supportive
treatment followed by TFT [32].
Further research on the treatment of CA-PTSD is
needed because of limitations of existing studies. Firstly,
no studies have directly compared TFT with PBT or
iTFT [15, 18, 33]. Secondly, patients with comorbidities
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such as dissociation, suicidality and personality disorders
have often been excluded from RCTs, limiting the
generalizability of the results to the population of
CA-PTSD [15, 29, 34, 35]. Thirdly, in most studies par-
ticipants were predominantly Caucasian and employed,
while PTSD is more severe in patients who are un-
employed or from minority ethnical backgrounds
[15, 29, 36, 37]. Fourthly, many studies have methodo-
logical shortcomings such as a lack of blind assessments
and no reported data on treatment integrity [15].
Allegiance effects – the unintentional bias due to inves-
tigators’ or therapists’ preferences [33, 38] – is a gen-
eral problem in clinical research. This may be solved by
involving researchers with different areas of expertise
and allegiances [39].
Current study
The aim of the current study is to examine the effective-
ness of three different treatment strategies for patients
with CA-PTSD. We will carry out a randomized con-
trolled trial (RCT) comparing the (cost-)effectiveness and
treatment adherence of a well-established form of TFT,
prolonged exposure (PE), with two potential improve-
ments of TFT: intensified PE (iPE) and phase-based treat-
ment (PBT). For the iPE group, PE sessions are delivered
in 4 weeks (3 sessions per week), PBT consists of Skills
Training in Affective and Interpersonal Regulation
(STAIR), followed by PE. We expect more PTSD
symptom reduction and lower drop-out rates in iPE
and PBT than in PE. We also expect that iPE and PBT
will be more cost-effective, given that the treatment
protocols include fewer (iPE) and shorter (PBT) sessions.
We expect that iPE will lead to faster improvement than
PE and PBT. Finally, we expect that PBT will be superior
to both PE and iPE with respect to improvement in emo-
tion regulation, interpersonal skills and self-esteem. The
primary outcome is clinician-rated PTSD symptom sever-
ity. Secondary outcomes are loss of PTSD diagnosis,
self-reported PTSD symptom severity, treatment adher-
ence, comorbid symptoms severity and cost-effectiveness.
Outcomes will be assessed at baseline, after 4, 8 and 16
weeks and at 6 and 12months follow-up.
Moderators and mediators
In line with previous work [40], we will investigate
whether treatment effects are affected by baseline charac-
teristics such as PTSD symptom severity, comorbid symp-
toms, emotional maltreatment and avoidance behavior,
using between- and within-group moderation tests. We
will calculate a ‘personalized advantage index’ (PAI) [41]
and trees for treatment-subgroup interactions (QUalitative
INteraction Trees; QUINT) to evaluate which pretreat-
ment characteristics are most discriminating in predicting
optimal treatment and differential response to treatments
with a combination of predictor variables. This may lead
to the development of optimal (personalized) treatment
sequences [41–43].
As to mediators, moderately strong evidence exists that
between-session habitation and change in post-traumatic
cognitions mediate the effects of PE, while mixed evidence
exists for emotional engagement, inhibition learning and
within-session habituation [44]. Mediators of iPE are yet
unknown. With regard to PBT, there is some evidence for
the mediating effect of both emotion regulation improve-
ment and therapeutic alliance on PBT outcome [31, 45].
More research on mediators is needed, as the number and
quality of the studies are limited [44]. In the current study
we will examine all above mentioned mediators.
Methods
Design
The IMPACT study is a multicenter RCT comparing pro-
longed exposure (PE) with intensified prolonged exposure
(iPE) and phase-based treatment (PBT). Participants will be
randomly assigned to the conditions. Figure 1 depicts the
study flowchart. The research protocol has been approved
by the Medical Ethical Committee of Leiden University
Medical Center (NL57984.058.16), and is pre-registered at
https://clinicaltrials.gov/ct2/show/NCT03194113.
Recruitment
Participants are recruited at the departments of Psycho-
trauma of PsyQ Den Haag and PsyQ Rotterdam. Refer-
rals from other treatment centers will also be accepted.
After initial screening, potential participants will receive
written and oral information about the study. Patients
who are interested in participating are invited for the
baseline assessment including screening of in- and ex-
clusion criteria and an informed consent procedure. In-
formed consent will be obtained prior to the assessment.
Participants
Inclusion criteria of the study are: 1) age 18–65; 2) diag-
nosis of PTSD as established with the Clinician Admin-
istered PTSD Scale (CAPS-5, see instrument section),
and at least moderate severity of PTSD-symptoms
(CAPS ≥26), and with at least one specific memory for a
traumatic event; 3) multiple traumata related to childhood
sexual and/or physical abuse that occurred before 18 years
of age, committed by a primary caretaker or an authority
figure as index event; 4) sufficient fluency in Dutch to
complete the treatment and research protocols.
Exclusion criteria are: 1) involvement in a compensation
case or legal procedures concerning admission or stay in
The Netherlands; 2) pregnancy; 3) severe non-suicidal
self-injury (NSSI) which required hospitalization during
the past three months; 4) severe suicidal behavior: a suicide
attempt during the past three months or acute suicidal
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ideations with serious intent to die with a specific plan for
suicide and preparatory acts; 5) severe disorder in the use
of alcohol or drugs in last three months; 6) cognitive im-
pairment (estimated IQ < 70); 7) changes in psychotropic
medication in the two months prior to inclusion; and 8)
engagement in any current psychological treatment.
Sample size
Our sample size calculations are based on the intention to
detect at least moderate effect size differences (d = .40)
among conditions. To detect this effect size difference in
PTSD severity with alpha = .05 (2-tailed) and a power of
0.8, 50 participants per condition are needed. We expect
some drop-out which will result in a lower power due to
missing values. However, we calculated the sample size
based on the conservative assumption that the correl-
ation between the baseline and all further post mea-
surements is 0 and the correlation between post
measurements is 1, since we do not have a good esti-
mation for the correlation between the outcome mea-
surements yet. Thus, the actual power is expected to
be considerably higher than 0.8 due to the multiple
measurement design correcting for power loss due to
drop-out [46, 47].
Procedure
Before randomization, patients complete a baseline as-
sessment of the study. In the preparatory session, pa-
tients receive detailed information about the treatment
and research procedures and about practical consider-
ations, such as availability. Randomization is carried out
by an independent researcher from Leiden University
who uses a computerized randomization sequence of
permutated blocks of six patients, stratified by gender.
Patients are regarded as treatment drop-out if they stop
therapy prematurely and as measurement drop-out if
Fig. 1 Flowchart of the IMPACT study
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they refuse or do not show up for follow-up measure-
ments. Early responders are defined by a score below 16
on the PTSD checklist for DSM-5 (PCL-5) for three
consecutive weeks with agreement between patient, ther-
apist and supervisor about finishing the therapy early
[48, 49]. Measurements will take place at baseline, dur-
ing the therapy (after 4 weeks, 8 weeks and 16 weeks) and
follow-up measurements after 6 and 12months. All mea-
surements are performed by trained and supervised inter-
viewers, who are blind to treatment condition. Patients and
their therapists also fill out self-report questionnaires before
therapy sessions and fill out questionnaires about harm
expectancies and distress during the exposure therapy.
Therapists and training
Before participation in the trial, master’s level therapists
attend a two-day training in prolonged exposure and a
two-day training in STAIR. At the end of these trainings,
the therapists have to pass an exam with pilot patients,
which is graded by the supervisors of the study. During
the study, all therapists receive weekly supervision in
(i)PE (by AM and RK) and PBT (by MC and IW). All
treatment locations offer the three types of treatment
and all therapists receive the same amount of supervi-
sion and training. Adherence to the treatment protocols
will be checked by independent observers, who will rate
randomly selected videotaped therapy sessions.
Prolonged exposure therapy
Prolonged exposure therapy (PE) is delivered in 16
weekly sessions of 90 min. The treatment manual is
based on the PE protocol by Foa, Hembree, & Rothbaum
(2007) [50].
Treatment sessions consist of imaginal exposure (re-
peated recounting of the most anxiety provoking traumatic
memories and processing related thoughts and feelings),
and exposure in vivo (approaching trauma-related situa-
tions). Between sessions, participants listen to audio re-
cordings of the imaginal exposure on a daily basis, and
complete in-vivo homework assignments.
Intensified prolonged exposure therapy
Intensified prolonged exposure therapy (iPE) involves
three weekly sessions of 90 min PE for a period of four
weeks (12 sessions total), followed by two PE sessions
after one and two months (14 sessions total). The same
protocol is used as in the PE condition with some minor
changes for practical considerations. For instance, when
two treatment sessions are given on consecutive days pa-
tients are instructed to do combined homework of both
sessions. After the first 12 sessions, patients are instructed
to keep doing imaginal exposure and exposure in vivo
homework for the 13th and 14th sessions. For practical
considerations, two therapists deliver the iPE sessions
alternately.
Phase-based therapy
Phase-based therapy (PBT) is delivered in 8 weekly 60
min STAIR sessions [51], followed by 8 weekly 90 min
PE sessions. STAIR is a manualized skills training,
adapted from dialectical behavior therapy and cognitive
behavioral therapy [52]. The first four STAIR sessions
focus on improving emotion regulation skills, including
labeling and identifying feelings, emotion management,
distress tolerance and the acceptance of feelings and
experiencing positive emotions. The last four STAIR ses-
sions focus on developing interpersonal skills and ad-
dress exploration and revision of maladaptive schemas,
the conflict between trauma generated feelings and
interpersonal goals in the present, differences in power
and control and flexibility in interpersonal situations
with differences in power [31]. Throughout the treat-
ment, patients receive psychoeducation, especially about
the connection between the traumatic events during
their childhood and the effect it has on their present
thoughts, feelings and behavior. After these eight ses-
sions the protocol continues with the standard PE proto-
col [50]. This differs from the standard STAIR protocol,
which continues with the Narrative Story Telling (NST)
protocol [53].
Instruments
In Table 1, an overview is presented of all the included
measures and measurement points.
Clinician-rated PTSD symptom severity
PTSD diagnosis and symptom severity are assessed with the
Clinical Administered PTSD scale (CAPS-5) [54]. The
CAPS-5 has recently been validated for the DSM-5
diagnosis of PTSD and has been translated into Dutch [55].
The CAPS-5 has good correspondence with CAPS-4
(kappa = .83) for the diagnosis of PTSD and a high internal
consistency (α= .88) and test-retest reliability (ICC = .78) for
the total severity score [56]. Response to the treatment is
defined as an improvement of at least 6 points on the
CAPS-5 [57]. Remission is defined as response to treatment,
loss of diagnosis and a symptom severity score below 26.
Self-reported PTSD symptom severity
Posttraumatic symptom severity is also measured with
the PTSD checklist for DSM-5 (PCL-5). The PCL-5 has
a high internal consistency (a = .94) and test-retest reli-
ability (r = .82) [58, 59].
Comorbid symptom severity
To measure clinician-rated symptoms that have been
proposed to define complex PTSD [28] we use three
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clinical administered items measuring problems with
emotion regulation, interpersonal difficulties and low
self-esteem (Complex PTSD items, CPI). Emotion regula-
tion, interpersonal difficulties and self-esteem are also
assessed with the Trauma Questionnaire of the Inter-
national Classification of Diseases, 11th edition (ICD-11)
[60]. Additionally, emotion regulation difficulties are mea-
sured with the Difficulties in Emotion Regulation Scale
(DERS) [61]. Interpersonal problems are measured with
the Inventory of Interpersonal Problems (IIP-32) [62, 63]
and self-esteem with the Rosenberg Self-Esteem Scale
(RSES) [64]. Clinician-rated dissociative symptom severity
Table 1 Overview of the measurements per time point
Clinical interview Construct T0 T1 T2 T3 T4 T5
MINI Axis-1 disorders X X X X
CAPS-5 PTSD X X X X X X
CPI Complex PTSD X X X X X X
SCID II Personality disorders X X
DSP-I Dissociation X X X X X X
Self-report
Demographics Demographics X
LEC-5 Traumata X
CTQ Childhood maltreatment X X
PCL-5b PTSD symptoms X X X X X X
DERSb Emotion regulation X X X X X X
ICD-11 Complex PTSD X X X X X X
BDI-II Depression X X X X X X
PTCI Posttraumatic cognitions X X X X X X
DES Dissociation X X X X X X
SDQ-5 Somatoform Dissociation Questionnaire X X X X X X
DERS Emotion regulation X X X X X X
TIC-P Direct/indirect costs X X X X
IIP Interpersonal problems X X X X X X
MOS Social support X X X X X X
RSES Self-esteem X X X X X X
ZAV Anger X X X X X X
ACS Attentional control X X X X X X
LEIDS Cognitive reactivity X
Treatment credibility Treatment credibility X X
Treatment Goals Treatment goals X
EQ-5L5D Quality of life X X X X X X
WAIa Working alliance
Cognitive task
Avoidance task Avoidance behavior X
Process variables Measurement moment
HE Harm expectancies Prior and after (imaginal) exposure
SUD Subjective distress Multiple times during (imaginal) exposure
MINI Mini-international Neuropsychiatric Interview, CAPS-5 Clinician Adminstered PTSD Scale, CPI Complex PTSD Items, SCID II Structured Clinical Interview for
DSM-IV axis-II personality disorders, DSP-I Dissociatief Subtype van PTSS, LEC-5 Life Events Checklist for DSM-5, CTQ Childhood Trauma Questionnaire, PCL-5 PTSD
Checklist for DSM-5, DERS Difficulties in Emotion Regulation Scale, ICD-11 International Classiciation of Diseases-11, BDI-II Beck Depression Inventory-II, PTCI The
posttraumatic cognitions inventory, DES Dissociative Experiences Scales, SDQ-5 Somatoform Dissociation Questionnaire-5, DERS Difficulties in Emotion Regulation
Scale; TIC-P Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness, IIP Inventory of Interpersonal Problems, MOS Medical Outcomes Study,
RSES Rosenberg Self-Esteem Scale, ZAV Zelf Analyse Vragenlijst, ACS Attentional Control Scale, LEIDS The Leiden Index of Depression Sensitivity, EQ-5D-5 L EuroQoL
5 Dimensions 5 Levels, WAI Working Alliance Inventory T0 = baseline, T1 = 4 weeks, T2 = 8 weeks, T3 = 16 weeks, T4 = 26 weeks, T5 = 52 weeks
aWAI is self-administered by the patient and therapist 4 times during the course of treatment before the start of the treatment sessions
bPCL-5 and DERS are self-administered weekly before the therapy session by the patient
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is measured with the two items about the dissociative sub-
type of PTSD in the CAPS-5. Also, we will also use a new
clinical interview for the Dissociative Subtype in PTSD
(DSP-I) [65]. Self-reported dissociative symptom sever-
ity is measured with the the Dissociative Experiences
Scale (DES) [66] and the Somatoform Dissociation
Questionnaire (SDQ) [67].
Comorbid axis-1 disorders (DSM-IV) are measured
with the Mini International Neuropsychiatric Interview
(MINI) [68]. Depression severity is measured with the
Beck Depression Inventory, 2nd edition (BDI-II-NL)
[69]. Cognitive reactivity and specifically suicidal re-
activity is assessed with the Leiden Index of Depression
Sensitivity (LEIDS) [70].
Personality disorders are measured with the Structured
Clinical Interview for DSM-IV Personality Disorders
(SCID-II) [71].
Moreover, anger, negative cognitions, social support and
attentional control are measured using self-report ques-
tionnaires State-Trait Anger Scale (ZAV) [72], the Post-
traumatic Cognitions Inventory (PTCI) [73, 74] the MOS
[75, 76] and the Attentional Control Scale (ACS) [76].
Trauma history
The LEC-5 [77, 78] measures any experienced traumatic
event and the CTQ (Childhood Trauma Questionnaire) will
be used to measure childhood trauma specifically [79, 80].
Treatment variables
Prior, during and immediately after (imaginal) exposure,
Subjective Units of Distress (SUD) ratings are assessed
and prior and after exposure harm expectancies are
assessed. Treatment credibility of the three therapies will
be checked with the adapted Treatment Credibility Scale
[81]. Additionally, the Working Alliance Inventory
(WAI) [82–84] will be used to examine therapeutic alli-
ance. The treatment goals of the patients are assessed
with an adapted version of the Bern inventory of treat-
ment goals [85].
Cost-effectiveness
Quality of Life is measured with the EQ-5D-5 L [86, 87].
The EQ-5D-5 L questionnaire will also be used as
cost-effectiveness measurement with the use of the social
tariffs of the EuroQol.
Moreover, cost-effectiveness is determined with the
Trimbos/iMTA questionnaire for costs associated with
Psychiatric Illness (TiC-P) [88] which measures the
(in)direct costs of illness (health care use and lost prod-
uctivity), and is specifically developed for the Dutch
Healthcare system.
Avoidance task
A classical associative learning paradigm is administered to
measure avoidance behaviors. In this task, emotional, anx-
iety provoking pictures from the International Affective
Picture System (IAPS)- set are used as unconditioned
stimulus (US), and pictures of an office containing a light,
that changes color (blue, red, yellow) as the conditioned
stimulus (CS). Participants can avoid the US by pressing a
button, but success is dependent on the CS [89].
Analyses
Data analyses will be based on intention-to-treat ana-
lyses. All randomized patients will be included in the
analyses. Due to the structured data, we will use multiple
imputation of multilevel data which takes the levels
within the data into account [90].
Primary and secondary continuous outcome parame-
ters will be analyzed with multilevel mixed models using
a repeated measurement design to correct for the de-
pendencies among the observations [91, 92]. Dichotom-
ous secondary outcome parameters will be analyzed with
multilevel logistic regression. The intraclass correlation
will be determined to give an indication about these
dependencies and determine the residuals which can be
explained within and between patients [92]. The models
will be fitted with the lme4 package in R and with a
FML estimation method [93]. The models will be nested,
so the models are compared with the likelihood ratio
test (LRT) [94]. All assumptions of the models will be
checked to ensure the reliability of the results. When
major assumptions are violated, clustered bootstrap will
be used, since this method can handle structured data
and has less stringent assumptions than multilevel
models. Cost-utility analysis will be based on patient re-
ports (societal costs per QALY), and cost-calculator
spreadsheet model (BIA). The economic evaluation will
also be based on analysis to treat; standard Dutch unit
prices will be used.
For moderation and mediation analyses, regression
based approaches will be used with the PROCESS macro
in SPSS [95]. For moderation analyses with multiple time
points, linear mixed models will be used with an inter-
action effect between time and the moderation variable of
interest. For between treatment moderation analyses the
three-way interaction between the moderator, treatments
and time will be calculated. For calculation of the person-
alized advantage index we will use leave-one-out cross
validation to generate the counterfactual prediction per
patient using prognostic and prescriptive variables from
moderation analyses and generate the PAI, the magnitude
of the predicted difference of receiving the predicted opti-
mal treatment versus the non-optimal treatment [41, 96].
For the Trees for treatment-subgroup interactions we will
use the R-package quint which uses a stepwise tree
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building algorithm to detect treatment by subgroup inter-
action allowing all possible predictor combinations in the
model. The algorithm subdivides all patients in terminal
nodes based on their patient characteristics and further
assigns patients to nodes in which either one of the treat-
ment is better than the other or both treatments are
equally effective [42, 43].
Discussion
Completion of this RCT will provide more knowledge
about the relative effectiveness of three treatment
strategies for CA-PTSD. We will directly compare the
effects of a well-established treatment (prolonged
exposure) and two treatment innovations (intensified
prolonged exposure and phase-based treatment) in
this difficult to treat patient population. Furthermore,
cost-effectiveness of the three interventions will be
examined. Finally, moderation and mediation analyses
will provide more information for whom and under
which conditions these treatments are most effective.
Ultimately, this might assist clinicians in personaliz-
ing treatment indications and optimizing treatment
delivery.
Methodological considerations
We expect to include a cultural and socioeconomic di-
verse sample, since the participating centers are located
in large cities. We protect the generalizability of the
findings by using few exclusion criteria. The relatively
long follow-up measurements of 6 and 12 months will
provide insights in the long-term effects of the therap-
ies. Every type of treatment is supervised by expert su-
pervisors of that specific method. Additionally, all
therapists are trained and supervised in both PE and
PBT. This prevents biases to the internal reliability of
the study and is essential for a meaningful interpret-
ation of the results [39].
Limitations of this study are that not all eligible pa-
tients will agree to participate in the study which could
result in selection bias. Especially the iPE condition
could lead to selection bias since it is more demanding
in terms of time investment in the first weeks of the
treatment. All reasons of patients to decline participa-
tion in the study will be carefully monitored to ensure
the generalizability of the results and for implementation
purposes. Another limitation is that patients have one
therapist in PE and PBT, but two alternating therapists
in the iPE condition. This may influence the therapeutic
alliance and consequently the results of the treatment.
We will assess whether therapeutic alliance indeed dif-
fers between condition and, if so, whether this has any
influence on treatment results.
Conclusion
Patients with CA-PTSD have a high burden of disease.
Currently, there is no consensus on treatment-guidelines
for this patient group. The results of this study may have
important implications for the treatment of patients with
CA-PTSD.
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